SENSEX 77414.92 ▼ (0.25%)
BSE BANKEX 59542.38 ▲ (0.36%)

ZIM Laboratories

BSE: 541400 30 Sep 2025
Healthcare
₹ 75.89
ZIM Laboratories Limited specializes in Pharmaceuticals within the Healthcare sector.

ZIM Laboratories - Share Price & Details

Market Cap
₹357.0
High /Low
128.0 / 69.1
Stock P/E
38.0
Book Value
₹51.8
Dividend Yield
0.0
ROCE
8.16
ROE
₹4.96
Face Value
10.0
PEG Ratio
-6.57
EVEBITDA
₹10.2
Debt
118
CMP / FCF
-19.6
Debt to equity
₹0.47
NP Ann
12.2
High price all time
153.0
Piotroski score
₹7.0
Graham Number
47.4
No. Eq. Shares
4.87
Net CF
₹-7.65
Net profit
9.39
Price to book value
1.41
Interest Coverage
₹2.21
Low price all time
14.0
Industry PE
33.0
Reserves
₹204
Free Cash Flow
₹1.08

Broker Recommendations

No broker recommendations available

We couldn’t find any recent recommendations for this company (matched by symbol or BSE code). Please check back later.


Price Chart


Volume Chart


Peer Comparison

Stock Total Income Net Profit Net Sales EPS Market Cap (in Cr) P/E
FABINO ENTERPRISES LIMITEDNANANANA5.0984.8
Triochem Products Ltd.,NANANANA0
ZIM Laboratories Limited729.03-16.92714.28-0.35357.038.0
SMS Lifesciences India Ltd800.5251.58790.4317.0634720.1
Trident Lifeline LimitedNANANANA34321.4

Peer Comparison Chart


About ZIM Laboratories

ZIM Laboratories Limited, with Security Code 541400, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.


Order Book


Latest News

ZIM Lab Standalone June 2025 Net Sales at Rs 71.43 crore, down 12.9% Y-o-Y

(22 Aug 2025)
Quarterly Net Loss at Rs. 1.69 crore in June 2025 down 322.91% from Rs. 0.76 crore in June 2024. EBITDA stands at Rs. 5.81 crore in June...
Read more →

Zim Laboratories Faces Continued Challenges Amidst Ongoing Market Volatility and Declining Performance

(19 Aug 2025)
Zim Laboratories has faced significant volatility, reaching a new 52-week low and continuing a downward trend. The company has reported five...
Read more →

Zim Laboratories Faces Significant Volatility Amid Broader Market Declines in Pharmaceuticals Sector

(16 Aug 2025)
Zim Laboratories has faced significant volatility, reaching a new 52-week low amid a streak of losses. The stock is trading below all major moving averages,...
Read more →

Zim Laboratories Faces Continued Challenges Amid Significant Stock Decline and Weak Financial Metrics

(11 Aug 2025)
Zim Laboratories has faced significant challenges, hitting a new 52-week low and continuing a downward trend. The company has reported negative results for...
Read more →

ZIM Laboratories granted marketing authorization for Tamsulosin + Dutasteride capsules in Australia

(09 Aug 2025)
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the...
Read more →

Zim Laboratories Faces Significant Volatility Amid Weak Fundamentals and Sector Underperformance

(09 Aug 2025)
Zim Laboratories has faced significant volatility, reaching a new 52-week low of Rs. 75.1 and underperforming its sector.
Read more →